A multicenter, open label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005% in pediatric subjects (ages 2 to 11 years) with plaque psoriasis.

Main Article Content

Adelaide A Herbert
Debbie Glaab
Rhonda Schreiber

Keywords

psoriasis, calcipotriene, pediatric

Abstract

Abstract not available.

References

1. National Psoriasis Foundation (2019, July 31). About Psoriasis. Retrieved from Psoriasis.org: www.psoriasis.org/parents/about psoriasis.

2. Silverberg, NB. (2009). Pediatric Psoriasis: An Update. Therapeutics and Clinical Risk Management, 5, 849-856.

3. Kimball, A Gold, M Zib B Davis, M. Clobetasol Propionate Emulsion Formulation Foam Ph. (2008). Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase
III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. JAAD, 59(3), 448-454.

4. Shah, KN (2013). Diagnosis and Treatment of Pediatric Psoriasis: Current and Future. American Journal of Clinical Dermatology, 14, 195.

5. Wolverton SE (2001). Comprehensive Dermatologic Drug Therapy (XlX ed.). Philadelphia, PA: Saunders.

6. Feldman SR, Mills, M Brundage, T Eastman, WJ. (2013, March). A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005% vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. JDD, 12(3), 300-306.

7. Hebert, A Glaab, D Schrieber R. (2019). A Phase 1 Open
Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005% Applied Under Maximum Use Conditions in Adolescent Subjects with Plaque Psoriasis. SKIN: The Journal of Cutaneous Medicine, 3(2).